In conclusion, we found that the intercalated combination of chemotherapy and EGFR TKIs significantly improved OS, PFS, and ORR compared to chemotherapy alone for the treatment of advanced NSCLC and significantly improved PFS and ORR compared to EGFR TKI monotherapy. Here, EGFR is linked to non-small cell lung carcinoma.